Wasatch Advisors
CCCC icon

Wasatch Advisors’s C4 Therapeutics CCCC Stock Holding History

Wasatch Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.9M Buy
4,160,048
+637,404
+18% +$2.38M 0.1% 120
2026
Q2 		$16.5M Buy
3,522,644
+560,883
+19% +$1.92M 0.11% 123
2026
Q1 		$7.79M Sell
2,961,761
-1,383,157
-32% -$3.26M 0.05% 138
2025
Q4 		$8.3M Sell
4,344,918
-507,823
-10% -$1.2M 0.05% 153
2025
Q3 		$10.8M Sell
4,852,741
-2,571,921
-35% -$6.17M 0.06% 149
2025
Q2 		$10.6M Buy
7,424,662
+700,253
+10% +$1.02M 0.06% 154
2025
Q1 		$10.8M Buy
6,724,409
+651,808
+11% +$1.94M 0.06% 155
2024
Q4 		$21.9M Buy
6,072,601
+395,233
+7% +$1.97M 0.11% 130
2024
Q3 		$32.4M Buy
5,677,368
+830,218
+17% +$5M 0.16% 114
2024
Q2 		$22.4M Buy
4,847,150
+518,671
+12% +$3.09M 0.12% 123
2024
Q1 		$35.4M Sell
4,328,479
-2,810,470
-39% -$21.8M 0.18% 109
2023
Q4 		$40.3M Buy
7,138,949
+891,808
+14% +$2.03M 0.22% 101
2023
Q3 		$11.6M Sell
6,247,141
-952,350
-13% -$2.9M 0.07% 137
2023
Q2 		$19.8M Buy
7,199,491
+1,483,470
+26% +$4.77M 0.12% 129
2023
Q1 		$17.9M Sell
5,716,021
-59,677
-1% -$351K 0.11% 137
2022
Q4 		$34.1M Sell
5,775,698
-158,778
-3% -$1.32M 0.23% 97
2022
Q3 		$52M Buy
5,934,476
+267,818
+5% +$2.78M 0.36% 75
2022
Q2 		$42.7M Buy
5,666,658
+4,128,133
+268% +$36.3M 0.27% 94
2022
Q1 		$37.3M Buy
1,538,525
+243,063
+19% +$5.9M 0.18% 110
2021
Q4 		$41.7M Sell
1,295,462
-46,585
-3% -$1.84M 0.17% 120
2021
Q3 		$60M Sell
1,342,047
-47,442
-3% -$2.03M 0.24% 102
2021
Q2 		$52.6M Buy
1,389,489
+304,482
+28% +$10.9M 0.21% 100
2021
Q1 		$40.1M Buy
+1,085,007
New +$43.2M 0.18% 109

Other funds holding CCCC

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
CV Advisors
CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Owl Creek Wealth Partners
Owl Creek Wealth Partners Denver, Colorado $355M AUM
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Wasatch Advisors's CCCC Position: Q3 2026 in Review

Wasatch Advisors increased its C4 Therapeutics (CCCC) stake by 18% in Q3 2026, buying an estimated $2.38M and bringing the position to 4,160,048 shares worth $13.9M. The position accounts for 0.1% of the portfolio, ranked #120.

Wasatch Advisors first reported a position in CCCC in Q1 2021 and has held it in 23 quarters since. The position peaked at $60M in Q3 2021. 8 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Wasatch Advisors held 4,160,048 shares of C4 Therapeutics worth $13.9M as of Q3 2026.
  • Wasatch Advisors bought 637,404 C4 Therapeutics shares in Q3 2026, an estimated $2.38M.
  • C4 Therapeutics made up 0.1% of Wasatch Advisors's portfolio in Q3 2026, its #120 holding.
  • Wasatch Advisors first reported a position in C4 Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • Wasatch Advisors's C4 Therapeutics position peaked at $60M in Q3 2021.
  • 8 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Wasatch Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.